森萱医药
(830946)
| 流通市值：53.13亿 | | | 总市值：53.15亿 |
| 流通股本：4.27亿 | | | 总股本：4.27亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 388,292,807.26 | 272,084,703.46 | 137,674,996.19 | 589,560,024.01 |
| 营业收入 | 388,292,807.26 | 272,084,703.46 | 137,674,996.19 | 589,560,024.01 |
| 二、营业总成本 | 280,612,605.13 | 188,944,959.26 | 97,935,912.87 | 427,327,950.06 |
| 营业成本 | 219,229,158.2 | 152,461,869.38 | 77,335,849.23 | 335,980,185.9 |
| 税金及附加 | 4,986,962.87 | 3,294,017.34 | 1,736,537.2 | 7,066,385.94 |
| 销售费用 | 11,348,175.29 | 7,791,238.66 | 3,612,552.15 | 15,074,846.21 |
| 管理费用 | 41,365,002.22 | 26,664,981.54 | 12,548,691 | 56,175,633.1 |
| 研发费用 | 22,856,171.16 | 14,524,720.34 | 7,116,442.26 | 28,177,102.17 |
| 财务费用 | -19,172,864.61 | -15,791,868 | -4,414,158.97 | -15,146,203.26 |
| 其中:利息费用 | 535,558.76 | 452,080.41 | 229,865.06 | 948,266.16 |
| 其中:利息收入 | 20,303,787.34 | 14,997,440.81 | 3,832,796.92 | 14,531,384.19 |
| 加:公允价值变动收益 | 1,386,469.86 | 1,138,358.75 | 1,011,969.86 | 3,044,254.79 |
| 加:投资收益 | 957,391.69 | 769,225.02 | -1,981.66 | 883,286.46 |
| 资产处置收益 | - | - | - | -66,240.84 |
| 资产减值损失(新) | -228,657.89 | -889,544.95 | 390,262.79 | -3,881,006.43 |
| 信用减值损失(新) | -613,608.27 | -1,386,165.2 | -405,558.81 | 1,524,093.98 |
| 其他收益 | 2,824,326.02 | 2,362,595.46 | 1,223,389.12 | 2,540,386.83 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 112,006,123.54 | 85,134,213.28 | 41,957,164.62 | 166,276,848.74 |
| 加:营业外收入 | 7,002.39 | 6,001.2 | 2,500.27 | 114,607.39 |
| 减:营业外支出 | 3,433,430.92 | 2,532,740.92 | 2,520 | 965,758.72 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 108,579,695.01 | 82,607,473.56 | 41,957,144.89 | 165,425,697.41 |
| 减:所得税费用 | 14,954,789.36 | 11,913,912.49 | 5,587,392.6 | 24,222,953.74 |
| 六、净利润 | 93,624,905.65 | 70,693,561.07 | 36,369,752.29 | 141,202,743.67 |
| 持续经营净利润 | 93,624,905.65 | 70,693,561.07 | 36,369,752.29 | 141,202,743.67 |
| 归属于母公司股东的净利润 | 91,366,685.53 | 69,680,607.02 | 34,861,755.22 | 134,523,788.78 |
| 少数股东损益 | 2,258,220.12 | 1,012,954.05 | 1,507,997.07 | 6,678,954.89 |
| (一)基本每股收益 | 0.21 | 0.16 | 0.08 | 0.32 |
| (二)稀释每股收益 | 0.21 | 0.16 | - | - |
| 九、综合收益总额 | 93,624,905.65 | 70,693,561.07 | 36,369,752.29 | 141,202,743.67 |
| 归属于母公司股东的综合收益总额 | 91,366,685.53 | 69,680,607.02 | 34,861,755.22 | 134,523,788.78 |
| 归属于少数股东的综合收益总额 | 2,258,220.12 | 1,012,954.05 | 1,507,997.07 | 6,678,954.89 |
| 公告日期 | 2024-10-29 | 2024-08-27 | 2024-04-29 | 2024-04-18 |
| 审计意见(境内) | | | | 标准无保留意见 |